A review of Friedreich ataxia clinical trial results
1Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA. sperlman@ucla.edu
Abstract:
There are now 21 agents or classes of therapeutic agents in the Friedreich ataxia research pipeline (http://www.curefa.org/pipeline.html) that have been developed in the 15 years since the discovery of the frataxin gene, with the ongoing characterization of its mutations and the resulting molecular pathology. Twenty-four studies are currently posted on ClinicalTrials.gov. Twenty-seven works discussing the results of clinical trials in Friedreich ataxia have been published. In 2010, 42 public (National Institutes of Health) and private (Friedreich Ataxia Research Alliance, Muscular Dystrophy Association, and National Ataxia Foundation) grants were funded for translational and clinical research in Friedreich ataxia. Millions of dollars from public, private, and industry-based initiatives have been dedicated to research in Friedreich ataxia therapeutics. Despite this vigorous international effort, there is as yet no proven disease-modifying therapy for Friedreich ataxia.
Insights
Despite significant investment and 15 years of research following the frataxin gene discovery, no disease-modifying therapy for Friedreich ataxia is yet available. Ongoing clinical trials and numerous research initiatives continue to seek effective treatments.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- The discovery of the frataxin gene has spurred significant research into Friedreich ataxia (FA).
- Understanding FA mutations and molecular pathology is crucial for therapeutic development.
- Numerous public and private funding initiatives support FA research.
Purpose of the Study:
- To review the current landscape of therapeutic agents and research efforts in Friedreich ataxia.
- To assess the progress made in developing disease-modifying therapies for FA.
- To highlight the gap between research investment and clinical outcomes.
Main Methods:
- Analysis of the Friedreich ataxia research pipeline, including therapeutic agents.
- Review of clinical trial data posted on ClinicalTrials.gov.
- Examination of published works discussing clinical trial results.
- Assessment of funding allocated to FA research from various sources.
Main Results:
- There are 21 therapeutic agents or classes in the FA research pipeline.
- Twenty-four studies are registered on ClinicalTrials.gov.
- Twenty-seven publications report on FA clinical trial results.
- Substantial public, private, and industry funding supports FA research.
Conclusions:
- Despite extensive research and investment, no proven disease-modifying therapy for Friedreich ataxia currently exists.
- The vigorous international effort has not yet yielded a successful treatment.
- Continued research and clinical trials are essential for advancing FA therapeutics.
Related Concept Videos
01:11Clinical Trials: Overview
01:24Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...